Toxicity Tests: “Inert” and Active Ingredients by Surgan, Michael H.
Missing Link?: Alachlor and
Semen Quality
The article by Swan et al. (2003) suggested
that alachlor exposure was linked to reduced
sperm quality in fertile men; after publica-
tion of the article, Monsanto (St. Louis,
MO) began a detailed examination of the
issue because the findings were entirely
unexpected and inconsistent with both our
information and the extensive published
literature on alachlor. Most surprisingly,
alachlor mercapturate (AM) was reportedly
found in the urine of 92% of study partici-
pants in Columbia, Missouri. Because this
metabolite arises exclusively from exposure
to the parent compound, few, if any, detects
would be expected based on declining
alachlor use (National Agricultural Statistics
Service 2005) and our detailed understand-
ing of its biological and environmental
properties (Feng et al. 1994). Also, extensive
water monitoring studies submitted to the
U.S. Environmental Protection Agency
(EPA) have shown that parent alachlor
occurs very infrequently in both potable
wells (Holden et al. 1992) and drinking
water from surface water sources (Hackett
et al. 2005), thereby calling into question
the plausibility of such widespread exposure.
We met with Swan and colleagues at the
University of Missouri in Columbia (UMC),
and with the personnel at the Centers for
Disease Control and Prevention (CDC)
who conducted the analyses, to discuss
our surprise at the findings. Our concern
about the reported frequent detections of
alachlor in urine was heightened when we
learned that the liquid chromatography/
mass spectrometry–mass spectrometry
method employed by the CDC (Olsson
et al. 2004) included no confirmatory ions,
a standard technique for avoiding false posi-
tives in the analysis of urine (Department of
Health and Human Services 1998). An
18-month collaboration ensued, which
included numerous discussions and a
round-robin study conducted between
Monsanto and the CDC, with involvement
by UMC researchers, to assess the perfor-
mance and transferability of the methods
used by each laboratory.
After successful completion of the round-
robin study, several frozen urine samples
retained from the original study were sent to
Monsanto. In results that we intend to sub-
mit for publication, we found no detectable
level of AM (limit of detection < 0.10 ppb)
in samples that the CDC reported to contain
up to 3 ppb (Swan et al. 2003). Sample
degradation does not explain this difference,
because we have data demonstrating AM sta-
bility under such conditions. Our analyses
followed Good Laboratory Practice standards
[U.S. Environmental Protection Agency
(EPA) 1989] and included confirmatory
ions. We also analyzed urine samples of
52 volunteers from agricultural areas across
North America, none of which actually con-
tained detectable AM, but 11 of which
showed false positives when confirmatory
ions were not used.
The CDC has now modified its method
to include confirmatory ions for alachlor.
We are confident that little or no AM would
have been detected had they included confir-
matory ions in the original analysis. The
CDC previously declined Monsanto's
request that they analyze the original samples
using a modified method with confirmatory
ions. However, after receiving an earlier ver-
sion of this letter, the CDC quickly per-
formed new analyses of 14 retained frozen
samples and informed us that analysis with
confirmatory ions validated their original
findings. Unfortunately, the CDC has not
provided us with sufficient data to confirm
the validity of the new method and results.
Monsanto continues to believe the detections
are spurious. From our perspective, the only
possible resolution of the matter at this time
would be for the retained samples to be sent
to an independent third-party laboratory for
confirmatory analysis.
We understand Swan et al. are now hav-
ing urine samples from other similar agricul-
tural areas analyzed using a confirmatory
method, and that AM is no longer being
routinely detected. This would affirm that
alachlor exposure is rare and the alleged link
to semen quality is implausible. It would be
very informative to identify the apparent
interferent using high-resolution mass spec-
trometry methodology, but our collaboration
has clearly shown that it was not AM. The
evidence presented by our analyses of the
samples provided by Swan, supported by our
successful performance in the round-robin
analysis of fortified samples, demonstrates
that the reported detections of alachlor were
most likely attributable to an interferent. The
data refute any link between alachlor exposure
and reduced sperm quality in fertile men.
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Editor’s note: Swan et al. chose not to
respond because the criticism was aimed at the
CDC; see Barr’s response below.
Missing Link: Barr and Needham
Respond
In January 2004, the Monsanto Company
contacted our laboratory at the Centers for
Disease Control and Prevention (CDC)
regarding their concern about the association
between alachlor (a Monsanto product) expo-
sure and semen quality reported by Swan
et al. (2003). As a result, we provided
Monsanto with detailed information about
our methodology for alachlor exposure assess-
ment by measuring its urinary metabolite
alachlor mercapturate (AM). In addition, we
participated in a study in which Monsanto
sent 25 urine samples to the CDC for analy-
sis. Monsanto had spiked 15 of these samples
with AM (< 1.5 ng/mL), and 10 unspiked
samples were collected from a field study; all
were blinded to the CDC. We did not detect
AM (> 0.1 ng/mL) in any of the field sam-
ples, including one with an alleged interfer-
ent; thus, the method did not produce
false-positive results. For the spiked urine
samples, the CDC and Monsanto measure-
ments showed excellent correlation (r =
0.9881; p < 0.0001), although the Monsanto
measurements averaged about 30% higher.
Similarly, the CDC sent samples representing
a broader range of concentrations (~ 1–100
ng/mL) to Monsanto for blinded analysis;
again, the results were comparable. 
At Monsanto’s request, residual samples
from those originally tested by Swan et al.
(2003) were sent to them for analysis.
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Monsanto pooled individual samples to pro-
duce three samples with concentrations of
< 0.1 ng/mL, approximately 0.2 ng/mL, and
approximately 3 ng/mL. Monsanto did not
detect AM in any of the pooled samples;
thus, they concluded that the CDC obtained
false-positive results possibly caused by a
putative interferent. We suggested that
Monsanto use the CDC method in its labo-
ratory to assess whether they observed the
interferent. Although Monsanto originally
agreed to do this, they reportedly did not
do so.
The addition of confirmation ions does
increase confidence in measurements,
although the method used by Swan et al.
(2003) was peer-reviewed, published in
Analytical Chemistry, and included many
components that produce highly reliable
results (Olsson et al. 2004). We have since
acquired technology that allowed us to mea-
sure AM with a similar limit of detection
while including confirmation ions. Using
both the older method (Olsson et al. 2004)
and a newer one (Norrgran et al., in press),
we analyzed 14 properly archived samples
that were split from samples originally ana-
lyzed and reported by Swan et al. (2003) and
compared all data. In these samples, the AM
levels were similar to those previously
obtained (r = 0.9912;  p < 0.0001)
(Norrgran et al., in press) and showed good
agreement using either method (r = 0.9999;
p < 0.00011) (Norrgran et al., in press). We
recently shared with Monsanto chro-
matograms of a urine sample with low levels
of AM as determined by all three analyses
and provided sufficient information with
which to evaluate the methodology.
Furthermore, we offered to discuss these
new results with Monsanto, but they have
not accepted this offer.
Finding AM concentrations in urine
samples collected in 2000 from men in
Missouri is not unlikely. Several studies
have detected alachlor with high frequency
in Midwestern groundwaters and surface
waters (Battaglin et al. 2000; Lerch and
Blanchard 2003) near the time and location
our sampling occurred. Thus, although we
do not frequently detect AM in general
population samples, we were not surprised
to find it in urine samples collected from
this region. Also, contrary to Gustafson’s
claim, we have not yet analyzed any field
samples from other agricultural areas using
our new method.
We strive to present quality human expo-
sure assessment data. We have been assessing
alachlor-related exposures since 1994; in fact,
we were the first to report that AM was the
primary human metabolite of alachlor
(Driskell et al. 1996). Our laboratory uses
both the highest caliber instrumentation and
isotopically labeled internal standards, which
result in high-quality, validated exposure-
assessment methods capable of producing
reliable and consistent results. Furthermore,
our laboratory is certified to analyze human
biological samples according to the Clinical
Laboratory Improvement Amendment
(1988), which requires extensive quality con-
trol and assurance, semiannual blinded profi-
ciency testing, continued verification and
documentation of operational parameters,
and recertification every 2 years.
We do not know why Monsanto did not
obtain similar results when analyzing pooled
urine samples left over from the original
analyses. Possible false-negative analyses
could result from multiple confirmation ions
that limit the sensitivity of detecting low
concentrations, degradation of AM in the
samples that had undergone several thaw-
refreeze cycles, or inadvertent dilution of AM
during the pooling process. However, the
results from our analysis of properly archived
specimens from 14 of the same persons from
the original study provide strong evidence
that our first analyses were, indeed, correct.
Perhaps, when we have more details on
Monsanto’s methodology and sample han-
dling procedures, we can further explore
potential reasons for the discrepancy between
our results.
The authors declare they have no competing
financial interests.
Dana B. Barr 
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National Center for Environmental Health
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Vinyl Chloride and U.S. EPA
Research
A commentary by Sass et al. (2005), “Vinyl
Chloride: A Case Study of Data Suppression
and Misrepresentation,” is itself a case study
in misrepresentation. The inclusion of such
an article in this peer-reviewed publication
stands in contrast to its stated mission to
publish “balanced” and “objective” informa-
tion. Sass et al. (2005) did not include or
address recent studies in characterizing the
weight of the scientific evidence related to
vinyl chloride and made inaccurate and
unsupported allegations about the integrity
of U.S. Environmental Protection Agency
(EPA) scientists and the rigorous peer review
process utilized by the U.S. EPA.
Sass et al. (2005) asserted that there is a
“scientific consensus that [vinyl chloride] is a
multisite carcinogen in humans and experi-
mental animals,” referencing 21 articles, only
3 of which were published during the past
15 years. They failed to mention or seriously
discuss 7 articles noted below that were pub-
lished in scientific journals since 1997 and
update many of the studies Sass et al. cited
and reach the opposite conclusion. These
and other recent peer-reviewed studies and
reviews fully support the U.S. EPA’s conclu-
sion that “the association [between vinyl
chloride and cancers other than the liver] is
weak and any estimated increase in mortality
from cancer at these sites is likely to be less
than for liver cancer” (U.S. EPA 2000).
Authors of these articles include Aaron
Blair, the chief of the Occupational Studies
Section of the National Cancer Institute
(NCI), who stated that epidemiologic evi-
dence shows a strong exposure–response
relationship for angiosarcoma of the liver,
but not for other types of cancer (Blair and
Kazerouni 1997). In a more recent review,
McLaughlin and Lipworth (1999) reached
the same conclusion: 
Occupational vinyl chloride exposure has not
been conclusively causally linked to any adverse
health outcome, with the exception of angio-
sarcoma of the liver.
Even more recently, Bosetti et al.
(2003) stated that 
The aggregate data are reassuring in excluding
any excess risk of death from lung, laryngeal, soft
tissue sarcoma, brain and lymphoid neoplasms, as
well as cirrhosis.
Recently published updates of cancer
incidence in European and American
industry-wide cohorts of workers exposed
to vinyl chloride provide a firm basis for the
conclusion that vinyl chloride exposure is
not causally associated with brain cancer and
the other tumors mentioned by Sass et al.
(2005). The European study (Ward et al.
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with the National Institute of Occupational
Safety and Health (NIOSH) and the
International Agency for Research on Cancer
(IARC). The authors found no evidence of
an increase in cancers other than the liver.
Similar, though less definitive, results were
published by Mundt et al. (2000) in an
update of the American cohort. A recent
meta-analysis of these cohorts by IARC sci-
entists further supports the conclusion
reached by the U.S. EPA (Boffetta et al.
2003). 
Given the strength and uniformity of the
evidence supporting the U.S. EPA’s position,
it is striking that Sass et al. (2005) did not
address it. Instead, they claimed that the
U.S. EPA yielded to advocacy by chemical
manufacturers, implying that the U.S. EPA
relied in part upon unpublished data. As
noted above, however, the articles upon
which the U.S. EPA placed primary reliance
are published, in a few cases, by academic
scientists sponsored by industry (e.g., Mundt
et al. 2000), but for the most part by scien-
tists affiliated with some of the most presti-
gious government-supported organizations
engaged in cancer research (e.g., NCI, IARC,
NIOSH). 
Finally, it is not accurate that industry
unduly influenced the review process for
vinyl chloride nor that the potency factors
published in the IRIS (Integrated Risk
Information System) database (U.S. EPA
2000) are insufficiently protective (Norman
2002). The former comment disparages the
U.S. EPA scientists who spent 5 years and
went through two external peer reviews to
make sure that relevant current science was
reflected. The latter fails to recognize that a
pharmacokinetic (PK) approach to risk
assessment was supported over 20 years ago
by the National Academy of Sciences and
that the PK model for vinyl chloride used
by the U.S. EPA—which predicted the
actual incidence of angiosarcoma of the liver
in the early cohorts of exposed workers—has
been peer-reviewed, published, and vali-
dated (Clewell et al. 2001; Reitz et al.
1996).
The author is employed by the American
Chemistry Council, a trade association represent-
ing the chemical industry, including manufac-
turers of vinyl chloride. The author has had,
may have, or may in the future have investment
interests in chemical companies, but does not
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Vinyl Chloride: Sass et al.
Respond
We provided documentation and extensive
references to support two claims: industry
urged the U.S. Environmental Protection
Agency (EPA) to downplay data suggestive
of cancer risks in tissues other than the liver,
and the U.S. EPA reduced the cancer
potency estimate of vinyl chloride in accor-
dance with industry input. The American
Chemistry Council (ACC) is a trade associa-
tion representing over 150 companies that
produce and use chemicals, including the
Dow Chemical Company (Midland, MI),
Georgia Gulf Corporation (Atlanta, GA),
and Occidental Chemical Corporation (Los
Angeles, CA) (ACC 2005). These three
companies are also full members of the Vinyl
Institute (Arlington, VA), whose stated goal
is to “promote and protect the vinyl industry
and the markets it serves” (Vinyl Institute
2005). Price, a lawyer with the ACC, main-
tains that our commentary is inaccurate
because a) studies published since 1997
“reach the opposite conclusion”; b)b y
demonstrating industry influence on the
U.S. EPA assessment of vinyl chloride we are
disparaging of U.S. EPA scientists; and c) the
pharmacokinetic (PK) model used by the
U.S. EPA has been “peer-reviewed, pub-
lished, and validated.”
In response to Price’s first point, recent
studies confirm earlier findings instead of
the opposite. At the time of the U.S. EPA
assessment (U.S. EPA 2000) there were over
20 scientific articles and two independent
reviews by the International Agency for
Research on Cancer (IARC 1979, 1987)
suggesting that vinyl chloride is a multisite
carcinogen in humans and experimental ani-
mals. Recent reviews and data support the
IARC conclusions. Of the references listed
by Price, three are reviews without new data
(Blair and Kazerouni 1997; Boffetta et al.
2003; Bosetti et al. 2003), two describe a
PK model (Clewell et al. 2001; Reitz et al.
1996), and two contribute new data that
neither refute previous studies nor support
ACC claims (Mundt et al. 2000; Ward et al.
2001). One of these is a North American
multicenter investigation, discussed in our
commentary, which reported modest
“excesses of brain cancer” and “cancer of
connective and soft tissue” (Mundt et al.
2000). The second new study is a European
multicenter investigation that is inconclusive
regarding risks of nonliver cancers (Ward
et al. 2001). Price also references a meta-
analysis that actually reported an excess in
brain cancer [standardized mortality ratio
(SMR) = 1.26; 95% confidence interval
(CI), 0.98–1.62) and soft-tissue sarcomas
(SMR = 2.52; 95% CI, 1.56–4.07) (Boffetta
et al. 2003); the authors of this meta-analy-
sis concluded that “increased mortality from
lung and brain cancers and from lymphatic
and hematopoietic neoplasms cannot be
excluded.” This is consistent with an Italian
study that reported increased lung cancer
deaths among polyvinyl chloride (PVC)
baggers (RR = 3.04; 95% CI, 1.15–7.99)
(Gennaro et al. 2003). 
Price’s letter and the U.S. EPA assess-
ment (U.S. EPA 2000) both reference a
review article by National Cancer Institute
authors (Blair and Kazerouni 1997). Blair
stressed that his findings do not support
disregarding possible risks of cancer outside
the liver and that potent carcinogens such
as vinyl chloride are unlikely to affect only
one organ site (Blair A, personal communi-
cation). In overall mortality, a slightly
increased rate of a common cancer such as
lung cancer may lead to more deaths than a
more markedly increased rate of a rare cancer
such as liver angiosarcoma. 
We believe that the U.S. EPA’s close
relationship with industry compromises
credibility. The ACC met with U.S. EPA
regulators to discuss a vinyl chloride assess-
ment at least 2 years before public notifica-
tion of an assessment process. At the urging
of the ACC (Price 1999), the U.S. EPA
eliminated a statement that there is “sugges-
tive epidemiological evidence that cancer of
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associated with vinyl chloride exposure. The
U.S. EPA also removed a 3-fold uncertainty
factor that had been included to account for
possible tumor induction at such sites, after
an ACC letter called the factor “ill advised”
(Price 1999). The result is that the U.S. EPA
assessment (U.S. EPA 2000) does not ade-
quately warn the public of the potential car-
cinogenicity of vinyl chloride suggested in
the scientific literature, and the risk estimate
is weakened 3-fold. 
The PK model has not been validated, as
stated by Price. The PK model developed by
industry consultants and used by the U.S.
EPA in its assessment has not been validated
because assumptions used in the model have
not been tested. Importantly, although the
model is limited to liver effects only, the
implicit assumption that all metabolism
occurs in the liver is incorrect (IARC 1987;
McFayden et al. 1998; U.S. EPA 2000). 
By using a model limited to liver cancer,
the U.S. EPA made a radical departure from
its cancer guidelines, recommending that the
cumulative risks of all tumor types be
included in a cancer assessment (U.S. EPA
1999, 2005). The 1999 carcinogen guide-
lines under which vinyl chloride was assessed
(U.S. EPA 1999) state that
In the analysis of animal bioassay data on the
occurrence of multiple tumor types, the cancer
potencies should be estimated for each relevant
tumor type that is related to exposure, and the
individual potencies should be summed for those
tumors.
This inclusive approach is reconfirmed in
the 2005 guidelines (U.S. EPA 2005). This
protective approach was not taken by the
U.S. EPA in its assessment of vinyl chloride
cancer risks. 
J.B.S and D.W. are employed by environ-
mental nonprofit organizations with an interest
in ensuring that regulations of toxic chemicals
are as health protective as feasible. B.C. is an
independent consultant in toxic substances con-
trol and has no competing financial interests
regarding the subject matter of this letter.
Jennifer Beth Sass
Health and Environment Program
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In their article, “Risk-Based Consumption
Advice for Farmed Atlantic and Wild Pacific
Salmon Contaminated with Dioxins and
Dioxin-like Compounds,” Foran et al.
(2005) present recommendations for con-
sumption of salmon containing dioxin-like
compounds (DLCs) based on three risk
assessment approaches.
Relying strictly on risk assessment to
develop fish consumption advice has many
shortcomings and may actually do more
harm than good (Arnold et al. 2005;
Egeland and Middaugh 1997). Risk assess-
ment is only part of the risk management
process when developing fish consumption
advice [U.S. Environmental Protection
Agency (EPA) 1996]. Other factors need to
be considered when developing fish con-
sumption advice, such as the nutritional
and health benefits of consuming fish and
the cultural, societal, and economic impacts
of reduced fish consumption (U.S. EPA
1996). Ignoring these factors may place an
undue burden on a local population by
removing a relatively inexpensive protein
source that would likely be replaced by a
less healthy substitute (Arnold et al. 2005;
Egeland and Middaugh 1997). Decisions to
limit fish consumption should only be
made at the local level because local public
health officials are most aware of the local
aforementioned impacts and the actual con-
centration of contaminants in locally caught
fish [Arctic Monitoring and Assessment
Programme (AMAP) 2002; Arnold et al.
2005; Hites et al. 2004]. 
In addition to measuring contaminant
concentrations in fish, human biomonitor-
ing is a very useful tool to measure actual lev-
els of contaminant exposure in targeted
“at-risk” populations rather than relying
solely on calculated estimates of exposure.
Biomonitoring should ideally be performed
in any identified at-risk population to verify
that a problem actually exists before advising
people to reduce fish consumption. This is
especially true in populations that rely on
locally caught fish as their primary protein
source and that have few inexpensive healthy
alternatives. Fortunately, recent evidence
suggests that the average concentration of
DLCs in the general U.S. population is
declining (U.S. EPA 2000). 
Two aspects of this study’s (Foran et al.
2005) methodology are problematic because
they lead to inappropriately conservative
estimates of health risk. First, the majority
of people in the United States do not eat
salmon skin, and as the authors noted, cook-
ing has been shown to reduce DLCs in fish
tissue. Because DLCs partition to fatty tis-
sues including skin, measuring DLCs in raw
fish with the skin on will overestimate the
amount of exposure to DLCs and over-
estimate the consumption risks. Second,
when assessing health risks posed by salmon
consumption, Foran et al. (2005) estimated
the number of meals of salmon per month
that would limit dioxin intake to 20% above
the U.S. average “background” adult intake
level of 65 pg toxic equivalents (TEQ)/day.
This approach ignores the fact that the
background rate incorporates both fresh-
water and saltwater fish consumption (U.S.
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CorrespondenceEPA 2000). In effect, Foran et al. (2005)
double counted dioxin exposure through
fish consumption. They also ignored the
fact that a person who chooses not to con-
sume a salmon meal would likely substitute
another protein source that also contains
trace quantities of DLCs. 
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Dioxin-Contaminated Farmed
Salmon: Foran et al. Respond
Middaugh et al. suggest that relying strictly
on risk assessment to develop fish consump-
tion advice has many shortcomings. We
agree. They also argue that risk assessment
is only part of the risk management process.
Although we separate risk assessment and
risk management, we agree conceptually
that risk management decisions often must
be based on more than just the results of a
quantitative risk assessment. 
What Middaugh et al. fail to recognize is
that our report on dioxins in salmon (Foran
et al. 2005) was not intended to serve as a
fish consumption advisory. Such advisories
should be left to appropriate state, federal,
and international organizations charged with
protection of public health. Rather, we
reported risk-based consumption advice that
would be triggered by dioxin-like com-
pounds (DLCs) in farmed Atlantic and
wild Pacific salmon using two different
approaches; the World Health Organization
(WHO) tolerable daily intake (TDI) for
DLCs and a margin-of-exposure approach
advocated by the U.S. Environmental
Protection Agency (EPA 2002). We also
reported cancer risks, based on the proposed
U.S. EPA cancer slope factor for DLCs (U.S.
EPA 2002) that would be generated at par-
ticular salmon consumption levels. Our
results demonstrate clearly that consumption
of some farmed Atlantic salmon, even at rela-
tively modest levels, raises human exposure
to DLCs above the lower end of the WHO
TDI and considerably above background
DLC intake for adults in the United States.
Further, consumption at these levels poses
elevated cancer and noncancer health risks. 
Middaugh et al. suggest that human bio-
monitoring should be used rather than rely-
ing on calculated estimates of exposure,
presumably to generate fish consumption
advice. We strongly disagree, particularly in
the case where the exposure source (farmed
Atlantic salmon) is not localized. This is a
global problem that would require human
biomonitoring on immense temporal and
spatial scales. In this case, quantitative risk
assessment, which includes an assessment of
chemical fate, transport, exposure, and
effects, is an appropriate surrogate for
human biomonitoring. Further, given our
vast knowledge of the toxicokinetic behavior
and toxicologic effects of dioxin and other
bioaccumulative compounds in farmed
Atlantic salmon, requiring human biomoni-
toring before issuing consumption advice is
akin to continuing a clinical trial of a drug
where unacceptable adverse effects have
already been demonstrated. Clearly, respon-
sible public health professionals should
strenuously object to such an approach. 
Middaugh et al. suggest that two aspects
of our study are problematic. First, they
argue that measuring contaminants in skin-
on fillets may overestimate contaminant
concentrations in edible fish tissue and,
ultimately, human exposure. We addressed
this issue in our article (Foran et al. 2005).
We encourage Middaugh et al. to reexam-
ine our conclusion that most studies of the
effects of preparation (including removal of
skin) and cooking on contaminant concen-
trations in fish tissue 
suffer from small sample sizes, questionable data
analyses, inconsistent analytical techniques, incon-
sistent data presentation, and variability in initial
and postintervention contaminant concentrations
within and among species, preparation techniques,
and cooking techniques. Deficiencies in study
design and variability in contaminant reductions
preclude development of a useful quantitative cor-
rection factor for the effects of preparation and
cooking on contaminant burden. As a result,
reductions in exposure and risk associated with
reduction in contaminant concentrations from
preparation and cooking cannot be evaluated
quantitatively; thus, we have not incorporated the
effects of cooking and preparation in our risk
assessments.
Second, Middaugh et al. are correct in
stating that we did not adjust for the exist-
ing background concentration that incorpo-
rates DLC exposure via fish consumption.
However, we did assess such exposures and
concluded that they were so low, compared
with exposure to DLC through consump-
tion of farmed Atlantic salmon, as to be
inconsequential in our risk assessment
calculations. 
Finally, we regret that Middaugh et al.
ignored two critically important conclu-
sions of our work. First, in all of our articles
(Hites et al. 2004a, 2004b; Foran et al.
2004, 2005) that address contamination of
salmon sold commercially, we provided
information that will allow and encourage
consumers to choose other fish, including
wild Pacific salmon, as well as other sources
of beneficial n-3 fatty acids. Second, our
work has exposed serious deficiencies and
inconsistencies in national and international
approaches to the management of contami-
nants in commercially sold fish. These defi-
ciencies and inconsistencies must be resolved
so that consumers can confidently choose
and consume fish with lower contaminant
concentrations while continuing to accrue
the health benefits of fish consumption.
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Disease and “Broken Windows”
Frumkin’s editorial in the May 2005 issue
of EHP (Frumkin 2005) was very interest-
ing and enlightening. On page A291,
Frumkin cited several studies that endorse
the “broken windows theory,” noting that 
Part of this effect may well be due to the disorder
and squalor of the environment. Poor people and
people of color are disproportionately exposed to
“broken windows.”
It is interesting that the “broken win-
dows” are considered to cause disease and
health inequity. What happened first: the
“broken windows,” or the lack of social
skills and the abandonment of the popula-
tion who live in such places? As a scientist, I
find it very difficult to accept that “broken
windows” are associated with the number of
cases of gonorrhea and are associated with
causality. The cases of venereal diseases
(VD) are more related to the social skills
and social behaviors of the people living in
the community. They also have a lack of
respect for property, and destruction of
property often occurs.
If we say the reverse is plausible, what
would happen if we got a grant and fixed all
of the “broken windows” in a particular
community, with no other intervention,
and observed the trend of VD? With the
assumptions and inferences made in
Frumkin’s editorial, this would have a posi-
tive effect in reducing cases of VD. My
instincts tell me that this would not be the
case. The “broken windows” are a conse-
quence of the behaviors of that particular
community and they are not the cause of
the behaviors. The “broken windows” are
what I consider “collateral damage” of
people lacking the necessary social skills to
overcome certain challenges, such as socio-
economic stress and the lack of mainte-
nance provided by building owners. These
people show their frustration and anger
many times against property, as well as
other people.
The author declares he has no competing
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“Broken Windows”: Frumkin
Responds
I thank Meléndez for his careful reading
of my editorial and for raising the very
reasonable question of whether “broken
windows”—an indicator of neighborhood
squalor—are causally related to poor
health. 
Clearly the relationship between fea-
tures of the built environment—including
signs of degradation and outcomes such as
behavior and health—is very complex.
Many of the causal arrows are probably
bidirectional. True clinical trials, which
might help disentangle and clarify specific
causal pathways, are difficult to carry out, as
Meléndez points out. However, at least two
interesting studies approximate a trial and
are informative. 
First, in the mid-1990s, former New
York City police commissioner William
Bratton implemented a “fixing broken win-
dows” approach—enforcing nuisance laws,
cleaning up graffiti, and so on. This
approach was credited with a substantial
subsequent decrease in street crime (Bratton
1995; Bratton and Knowlner 1998; Kelling
and Coles 1996). Second, the Moving to
Opportunity trial in the mid-1990s enrolled
over 3,000 families in high-poverty neigh-
borhoods of Baltimore, Maryland; Boston,
Massachusetts; Chicago, Illinois; Los
Angeles, California; and New York, New
York. They were randomly assigned to
receive housing vouchers usable in low-
poverty neighborhoods or to remain where
they were. Although the results were vari-
able, families moving to low-poverty neigh-
borhoods did experience improvements in
several aspects of physical and mental health
(Orr et al. 2003). So while these effects are
not simple, there is some evidence that less-
chaotic, disordered environments may pre-
dict better health. 
Perhaps the fundamental issue is that in
poor communities, environmental factors
and social factors are inextricably inter-
twined. Our efforts to understand their
effects on health, and to improve people’s
lives, need to focus on the root causes of
both poverty and environmental hazards.
The author declares he has no competing
financial interests.
Howard Frumkin





Bratton W, Knobler P. 1998. Turnaround: How America’s Top Cop
Reversed the Crime Epidemic. New York:Random House.
Bratton WJ. 1995. The New York City Police Department’s
civil enforcement of quality-of-life crimes. J Law Policy
3(3):447–464.
Frumkin H. 2005. Health, equity, and the built environment
[Editorial]. Environ Health Perspect 113:A290–A291.
Kelling G, Coles C. 1996. Fixing Broken Windows. New York:
Free Press.
Orr L, Feins JD, Jacob R, Beecroft E, Sanbonmatsu L, Katz LF,
et al. 2003. Moving to Opportunity for Fair Housing
Demonstration: Interim Impacts Evaluation. Washington
DC:U.S. Department of Housing and Urban Development,
Office of Policy Development and Research. Available:
http://www.huduser.org/Publications/pdf/MTOFullReport.
pdf (accessed 8 June 2005).
Toxicity Tests: “Inert” and Active
Ingredients 
The findings of Richard et al. (2005) are an
important addition to our understanding
that the health and environmental effects of
formulated pesticide products are not fully
reflected in tests conducted on the active
ingredient(s) alone. It has been long known
that the adjuvants (commonly and mislead-
ingly called “inert” ingredients) may be toxic
and may enhance or supplement the toxic
effects of the active pesticidal ingredient.
In the case of glyphosate-containing
products, this phenomenon was well demon-
strated in the data submitted to the (EPA) by
the registrant (Monsanto), and summarized
by the U.S. EPA in the Reregistration
Eligibility Document (RED) for glyphosate
(U.S. EPA 1993). For example, based on the
registrant’s own tests of acute toxicity to
freshwater fish, the U.S. EPA classified tech-
nical grade glyphosate as “slightly toxic” to
“practically non-toxic” and formulated prod-
ucts ranged from “moderately toxic” to
“practically non-toxic.” Tested alone, the
surfactant adjuvant (identified as “inert”) was
“highly toxic” to “slightly toxic.” Similar dif-
ferences were reported in tests of acute toxic-
ity to freshwater invertebrates.
Based in part on the data in the
glyphosate RED (U.S. EPA 1993), the New
York State Attorney General’s office success-
fully pursued an action against Monsanto in
1996 (Attorney General of the State of New
York 1996). At that time, Monsanto was
making advertising claims about the toxicity
of the Roundup products based on data
from tests on the active ingredient alone.
Such claims are scientifically unfounded and
inherently deceptive. The Attorney General’s
action was facilitated by the availability of at
least some limited information about the
inert ingredients and their toxicity. That
same sort of information enabled Richard
et al. (2005) to conduct their study. 
Unfortunately, that is not always the
case, and for many pesticide products, little
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ingredients is publicly available. Registrants
are generally required to conduct acute toxi-
city tests on formulated products, but they
traditionally conduct chronic toxicity tests
on the active ingredient alone. Even when
formulated products are tested, the identity
of inert ingredients is rarely revealed in the
open literature, publicly available regulatory
documents, or product labels. Therefore,
independent research is stymied, and the
public is ill-informed in the marketplace. 
The author is the chief scientist in the New
York State Attorney General’s Environmental
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the 1996 action against Monsanto.
Michael H. Surgan
Environmental Protection Bureau
New York State Attorney General’s Office
New York, New York
E-mail: michael.surgan@oag.state.ny.us
REFERENCES
Attorney General of the State of New York. 1996. In the Matter
of Monsanto Company, Respondent. Assurance of
Discontinuance Pursuant to Executive Law § 63(15). New
York:Attorney General of the State of New York,
Consumer Frauds and Protection Bureau, Environmental
Protection Bureau.
Richard S, Moslemi S, Sipahutar H, Benachour N, Seralini G-E,
2005. Differential effects of glyphosate and Roundup
on human placental cells. Environ Health Perspect
113:716–720.
U.S. EPA. 1993. Reregistration Eligibility Decision (RED).
Glyphosate. EPA-738-R-93-014. Washington, DC:U.S.
Environmental Protection Agency. Available: http://cfpub.
epa.gov/oppref/rereg/status.cfm?show=rereg [accessed
1 September 2005]. 
“Inert” and Active Ingredients:
Séralini Responds
Surgan raises interesting points in his analy-
sis. This interest has been confirmed by
reactions of agriculture authorities all over
the world after publication of the article by
Richard et al. (2005). 
Indeed, scientific problems do exist in the
registration of pesticides today, when chronic
toxicity tests are conducted with the active
ingredient alone—which is generally the case.
First of all, chemists from companies may
work hard for several years to find the right
formulation that best amplifies the effects of
the active ingredient. his formulation will
allow penetration and stability and/or bioac-
cumulation of the active ingredient within
plant, fungi, or insect cells, for instance, to
reach the best toxicity. If there are any side
effects in other animal or human cells, these
will be also amplified by adjuvants, and thus
not measured in chronic toxicity tests with the
active ingredient alone. The active compound
absorption by skin is generally calculated in
the presence of formulated adjuvants, but this
is clearly a short-term study and not sufficient
to detect, for example, endocrine disruption
or carcinogenesis, possibly promoted in vivo
by the described synergy. This should even
necessitate further care in case of the use of
formulated products such as glyphosate-based
herbicides on tolerant, edible plants.
As a matter of fact, most genetically
modified crops have been modified and
selected only to tolerate high-formulated her-
bicide absorption, but the plants are not sub-
mitted for registration requiring chronic
toxicity studies involving long-term feeding
of animals. Moreover, in the case of environ-
mental pollution, active pesticide ingredients
may encounter detergents or other lipohilic
xenobiotics with comparable effects other
than those of their own adjuvants, for
instance, forming microvesicles to penetrate
the cells. These combined effects should also
be taken into account in authorized thresh-
olds of pollution in order to avoid effects on
wildlife or humans.
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